Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 2
2009 1
2012 1
2015 1
2017 2
2018 3
2019 2
2020 1
2021 2
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.
Groeneveldt C, Kinderman P, Griffioen L, Rensing O, Labrie C, van den Wollenberg DJM, Hoeben RC, Coffey M, Loghmani H, Verdegaal EME, Welters MJP, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: van den wollenberg djm. Cancer Immunol Res. 2024 Mar 4;12(3):334-349. doi: 10.1158/2326-6066.CIR-23-0480. Cancer Immunol Res. 2024. PMID: 38194598 Free PMC article.
Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy.
Groeneveldt C, van Ginkel JQ, Kinderman P, Sluijter M, Griffioen L, Labrie C, van den Wollenberg DJM, Hoeben RC, van der Burg SH, Ten Dijke P, Hawinkels LJAC, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: van den wollenberg djm. Cancer Res Commun. 2023 Feb 23;3(2):325-337. doi: 10.1158/2767-9764.CRC-23-0019. eCollection 2023 Feb. Cancer Res Commun. 2023. PMID: 36860656 Free PMC article.
Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy.
Groeneveldt C, Kinderman P, van Stigt Thans JJC, Labrie C, Griffioen L, Sluijter M, van den Wollenberg DJM, Hoeben RC, den Haan JMM, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: van den wollenberg djm. J Immunother Cancer. 2022 Jul;10(7):e004464. doi: 10.1136/jitc-2021-004464. J Immunother Cancer. 2022. PMID: 35853671 Free PMC article.
Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models.
van de Merbel AF, van der Horst G, van der Mark MH, Bots STF, van den Wollenberg DJM, de Ridder CMA, Stuurman D, Aalders T, Erkens-Schulz S, van Montfoort N, Karthaus WR, Mehra N, Smits M, Schalken JA, van Weerden WM, Hoeben RC, van der Pluijm G. van de Merbel AF, et al. Among authors: van den wollenberg djm. Cancer Gene Ther. 2022 Jun;29(6):793-802. doi: 10.1038/s41417-021-00360-2. Epub 2021 Jun 16. Cancer Gene Ther. 2022. PMID: 34135475 Free PMC article.
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C, Kinderman P, van den Wollenberg DJM, van den Oever RL, Middelburg J, Mustafa DAM, Hoeben RC, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: van den wollenberg djm. J Immunother Cancer. 2020 Oct;8(2):e001191. doi: 10.1136/jitc-2020-001191. J Immunother Cancer. 2020. PMID: 33082167 Free PMC article.
23 results